Valuation: ZIM Laboratories Limited

Market Cap 6.09B 63.88M 55.44M 51.58M 47.39M 89.56M 90.99M 607M 239M 3.03B 240M 235M 10.16B P/E 2025
32.1x
P/E 2026 50.3x
Enterprise Value 6.96B 72.93M 63.29M 58.88M 54.1M 102M 104M 694M 273M 3.46B 274M 268M 11.6B EV / Sales 2025
1.34x
EV / Sales 2026 1.09x
Free-Float
28.79%
Yield 2025 *
-
Yield 2026 -
1 day-1.04%
1 week-5.17%
1 month-8.45%
3 months+29.29%
6 months+59.58%
Current year+58.30%
1 week 112.95
Extreme 112.95
120
1 month 111.5
Extreme 111.5
125.5
Current year 59.72
Extreme 59.72
133.95
1 year 59.72
Extreme 59.72
133.95
3 years 59.72
Extreme 59.72
151.75
5 years 36.37
Extreme 36.3667
151.75
10 years 14
Extreme 14
151.75
Manager TitleAgeSince
Chief Executive Officer - 31/12/2001
Director of Finance/CFO - 31/03/2019
Director of Finance/CFO - 31/12/1990
Director TitleAgeSince
Chairman - 31/12/1989
Director/Board Member - 31/12/1990
Director/Board Member - 31/12/2012
Change 5-day change 1-year change 3-year change Capi.($)
-1.04%-5.17%+3.27%-17.98% 63.84M
-0.53%+2.54%+16.63%+74.09% 50.03B
-1.81%-0.49%+51.99%+112.44% 36.6B
+0.46%+4.44%-5.24%+25.38% 12.47B
+1.05%+1.63%+16.19%+78.22% 11.77B
-1.33%-0.76%+30.08%+131.70% 9.04B
-2.99%-2.09%+41.02%-8.36% 7.03B
+0.51%+1.46%+12.17%+32.88% 6.79B
-.--%+0.14% - - 6.79B
+1.99%+1.91%+4.68%+183.54% 6.6B
Average -0.37%+0.38%+18.98%+67.99% 14.72B
Weighted average by Cap. -0.62%+1.27%+25.17%+82.80%

Financials

2025 2026
Net sales 3.79B 39.74M 34.49M 32.09M 29.49M 55.72M 56.61M 378M 149M 1.89B 149M 146M 6.32B 3.74B 39.25M 34.06M 31.69M 29.12M 55.03M 55.9M 373M 147M 1.86B 147M 144M 6.24B
Net income 122M 1.28M 1.11M 1.03M 946K 1.79M 1.82M 12.13M 4.77M 60.59M 4.79M 4.68M 203M 58.38M 612K 531K 494K 454K 858K 872K 5.82M 2.29M 29.08M 2.3M 2.25M 97.35M
Net Debt 1.16B 12.14M 10.53M 9.8M 9M 17.01M 17.28M 115M 45.38M 577M 45.57M 44.57M 1.93B 863M 9.05M 7.85M 7.31M 6.71M 12.68M 12.89M 86.04M 33.83M 430M 33.98M 33.23M 1.44B
Logo ZIM Laboratories Limited
ZIM Laboratories Limited is a pharmaceutical company. The Company develops, manufactures and supplies oral, solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) in various therapeutic segments. Its delivery solutions cover product conceptualization product development, filing for registration, manufacture, and supply of various pharmaceutical formulations. It is developing products in various therapeutic segments like, central nervous system, anti-biotic and anti-infective, gastrointestinal, cardiovascular, analgesic/pain management, urology and vitamins, minerals, and dietary supplements. Its technological capabilities include drug release modification, solubility and stability enhancement, taste masking and dosage form transformation. Its product offerings include finished formulations and pre-formulations intermediates, which include granules, pellets, taste-masked powders, dry suspensions, tablets, capsules, and oral thin films.
Employees
632
Date Price Change Volume
31/07/26 ₹113.80 -1.04% 1,157
30/07/26 ₹115.00 +1.68% 2,000
29/07/26 ₹113.10 -1.87% 636
28/07/26 ₹115.25 -2.00% 536
27/07/26 ₹117.60 -2.00% 995
  1. Stock Market
  2. Stocks
  3. ZIMLAB Stock